MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41375-021-01281-7

Медицинская библиотека · Leukemia · 2021

Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia.

Dourthe Marie-Emilie, Rabian Florence, Yakouben Karima, Chevillon Florian, Cabannes-Hamy Aurélie, Méchinaud Françoise, Grain Audrey, Chaillou Delphine, Rahal Ilhem, Caillat-Zucman Sophie, Lesprit Emmanuelle, Naudin Jérôme, Roupret-Serzec Julie, Parquet Nathalie, Brignier Anne, Guérin-El Khourouj Valérie, Lainey Elodie, Caye-Eude Aurélie, Cavé Hélène, Clappier Emmanuelle, Mathis Stéphanie, Azoulay Elie, Dalle Jean Hugues, Dhédin Nathalie, Madelaine Isabelle, Larghero Jérôme, Boissel Nicolas, Baruchel André

СтатьяПеревод пока не подготовлен

Аннотация

Tisagenlecleucel therapy has shown promising efficacy for relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, relapses occur in 30-50% of patients. Determinants for CD19pos versus CD19neg relapses are poorly characterized. We report on 51 patients with R/R BCP-ALL (median age 17 years) infused with tisagenlecleucel after lymphodepletion. Complete remission rate at D28 was 96%. Prior blinatumomab increased the risk of early failure at D28. The 18-month cumulative incidence of relapse (CIR), event-free survival (EFS), and overall survival (OS) were 51%, 44%, and 74%, respectively, at a median follow-up of 15.5 months. Factors associated with a high tumor burden (occurrence of cytokine release syndrome) and prior blinatumomab were associated with an increased CIR, and a shorter EFS and OS. Pre-lymphodepletion high disease burden (MRD ≥ 10-2, SHR 10.4, p = 0.03) and detectable MRD at D28 (SHR 7.2, p = 0.006) correlated with an increased risk of CD19neg relapse. Low disease burden (SHR 5.3, p = 0.03) and loss of B-cell aplasia (BCA) (SHR 21.7, p = 0.004) predicted an increased risk of CD19pos relapses. These data highlight the impact of prior therapy on patient outcome. Finally, detectable MRD at D28 and loss of BCA both define patients at high risk of relapse for whom additional interventions are needed.

Для цитирования: Dourthe Marie-Emilie, Rabian Florence, Yakouben Karima, Chevillon Florian, Cabannes-Hamy Aurélie, Méchinaud Françoise, Grain Audrey, Chaillou Delphine, Rahal Ilhem, Caillat-Zucman Sophie, Lesprit Emmanuelle, Naudin Jérôme, Roupret-Serzec Julie, Parquet Nathalie, Brignier Anne, Guérin-El Khourouj Valérie, Lainey Elodie, Caye-Eude Aurélie, Cavé Hélène, Clappier Emmanuelle, Mathis Stéphanie, Azoulay Elie, Dalle Jean Hugues, Dhédin Nathalie, Madelaine Isabelle, Larghero Jérôme, Boissel Nicolas, Baruchel André. Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia.. Leukemia. 2021. DOI: 10.1038/s41375-021-01281-7.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.